Featured Video
This Week in Quality Digest Live
Health Care Features
AssurX
Medical device manufacturers want clarity
Wesley McGrew
When the worm turns
AssurX
CDRH is walking the talk and expects device manufacturers to do the same
Rob Mitchum
Five promising trends toward improving patient care
Brooke Pierce
Use your data

More Features

Health Care News
The FDA’s RMAT designation goes live
New company will focus on technologies for the management and automation of vital clinical processes
Marking and cutting lasers used in manufacturing endoscopic devices and catheters
Technique provides about a sixfold improvement over regular microscopes
Awards help states implement multiyear produce-safety systems
How a hospital restored quality patient care and obtained financial stability using lean
A strategic guide to implementing lean for hospital leaders
The future of medical product development?

More News

BioCision

Health Care

BioCision Announces the Formation of MedCision

New company will focus on technologies for the management and automation of vital clinical processes

Published: Wednesday, December 14, 2016 - 15:24

(BioCision: San Rafael, CA) -- BioCision LLC, a life science research and development company that standardizes basic laboratory processes, has announced the formation of MedCision Inc., an independent company focused on automation of pre-clinical and clinical processes.

“The formation of MedCision is driven by a critical need in the market for innovative standardization technologies and solutions for translational, clinical, and point-of-care settings,” says Rolf O. Ehrhardt, M.D., Ph.D., BioCision CEO. “MedCision will be a leader in developing and commercializing innovative instruments for crucial processes in the post-manufacturing cell and gene therapy space.”

“The name of the company, MedCision, creates a clear connection to our BioCision roots but also conveys an evolution from those roots as our technology will focus on automating point-of-care clinical processes,” continues Ehrhardt.

The creation of MedCision as a stand-alone company with a dedicated management team will provide the necessary focus and foundation for long-term value generation in the clinical tools space. Commercialization of the award-winning ThawSTAR cell thawing platform will initially be the focus of MedCision.

Cell thawing, the last step a cellular product undergoes before patient administration, is one of the most important parts of the post-manufacturing process. Rapid, uniform, nonfluid-based thawing is necessary to maintaining therapeutic efficacy. ThawSTAR’s automated cell-thawing platform makes it easy to ensure proper clinical handling and thawing across a range of volumes and storage formats. At the same time, the platform automatically incorporates temperature monitoring and data connectivity, both of which are critical to ensuring proper sample tracking and patient safety.

The ThawSTAR platform is experiencing rapid adoption into cell therapy research and development as part of clinical trials and will accelerate with the soon-to-be-announced Early Adopter Program. As the flagship product of this new company, the ThawSTAR platform will be expanded over the next 12 months with additional models and features.

MedCision corporate offices will be headquartered in San Rafael, California, and spearheaded by former members of the BioCision senior management team. Rolf Ehrhardt will serve as president and CEO; Ron DiNocco, chief financial officer and vice president of corporate development; Eric Kunkel, senior vice president of research and development; and Sam Kent, senior vice president of global sales and business development.

For more information about MedCision, visit www.medcision.com. For business and partnership information, contact Samuel Kent at mailto:busdev@medcision.com.

Discuss

About The Author

BioCision’s picture

BioCision

BioCision LLC is a life-science research and development company that develops products and solutions for process standardization throughout the healthcare industry through the application of advanced thermal regulation principles and technologies. The intuitive design and interconnectivity of BioCision products enables researchers, clinicians, and manufacturers to protect the integrity of temperature-sensitive therapeutics, biological samples, and biomaterials. By comprehensively addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development and enable effective care delivery.